TITLE

Patents, Innovation and Access to New Pharmaceuticals

AUTHOR(S)
Grabowski, Henry
PUB. DATE
December 2002
SOURCE
Journal of International Economic Law;Dec2002, Vol. 5 Issue 4, p849
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This paper considers the role of intellectual property rights in the development of, and access to, new pharmaceuticals. A number of studies have found patents are significantly more important to pharmaceutical firms in appropriating the benefits from innovation compared with other high tech industries. The reason for this is because the costs of drug innovation are very high while the costs of imitation are relatively low. Hence the industry is subject to significant free‐rider problems. The paper discusses the economics of the innovative process and considers how patent policies have evolved in response to these characteristics in several developed countries with research‐intensive drug firms. One area currently receiving policy attention is the effect of patents on the development of, and access to, new medicines for developing countries. The final section of the paper focuses on this issue and discusses the need for an orphan drug type programme to stimulate more R&D on diseases specific to third‐world countries.
ACCESSION #
44548845

 

Related Articles

  • The Influence of TRIPS Compliant Patent Laws on Indian Pharmaceutical Industry. Rastogi, Rupesh; Kumar, Virendra // Adhyayan: A Journal of Management Sciences;Jun2014, Vol. 4 Issue 1, p1 

    The first legislation in India relating to patents was the Act VI of 1856. The Indian Patents and Design Act, 1911 (Act II of 1911) replaced all the previous Acts. The Act brought patent administration under the management of Controller of Patents for the first time. After Independence, it was...

  • Patent and Trademark Appeal Board to Determine Whether to Sanction Kyle Bass for Filing IPRs. QUINN, GENE // Inventors' Digest;Oct2015, Vol. 31 Issue 10, p39 

    The article focuses on the motion for sanctions filed by Celgene Corp. against the Coalition for Affordable Drugs (CAD) saying that filing the inter partes review by the CAD constituted an abuse of process. An opposition to the patent owner's motion for sanctions was filed by CAD and was waiting...

  • Pharma patents: India ranks second.  // Siliconindia;Sep2005, Vol. 9 Issue 8, p15 

    Reports on the increasing number of applications for patent of pharmaceutical products in India. Invention of critical life saving drugs by the pharmaceutical companies; Launch of drugs at a frenetic pace in Western countries; Attraction of international attention by the pharmaceutical firms...

  • PATENT DOCUMENTATION IN ASIAN AND EUROPEAN COUNTRIES: A MAJOR ROLE IN DRUG DEVELOPMENT. Deepika, Surendar Verma // International Journal of Pharmacy & Pharmaceutical Sciences;Mar2012, Vol. 4 Issue 2, p22 

    A Patent is an intellectual property right relating to inventions and is the grant of exclusive right, for limited period, provided by the Government to the patentee, in exchange of full disclosure of his invention, for excluding others, from making, using, selling, importing the patented...

  • Changing Role of Intellectual Property. Hunt, Thomas // Drug Discovery & Development;Apr2004, Vol. 7 Issue 4, p13 

    Looks on changes in the role of intellectual property in the pharmaceutical industry in the United States. Pharmaceutical companies' patenting of the formulation for drugs; Drug discovery and development; Companies' adoption of more strategic and proactive approach to intellectual asset...

  • US switch to first-to-file patents could cause minor shake-up. Waters, Hannah // Nature Medicine;Aug2011, Vol. 17 Issue 8, p906 

    The article focuses on the decision of the U.S. to switch to first-to-file system used by patent regulators and ways how patent overhaul can change the rules in intellectual property in the drug industry. Benjamin Roin of Harvard Law School in Cambridge, Massachusetts says that the U.S. will...

  • Open Innovation in Pharma: Defining the Dialogue. Waldron, Roy F. // Pharmaceutical Executive;Sep2012, Vol. 32 Issue 9, p54 

    The article presents the author's comments on the concept of open innovation in the pharmaceutical industry. According to the author, access to the right set of information may be the important environmental factor in lowering the risks and costs for those engaged in drug discovery. He adds that...

  • Are the Economics of Pharmaceutical Research and Development Changing? Productivity, Patents and Political Pressures. Grabowski, Henry // PharmacoEconomics;2004 Supplement, Vol. 22, p15 

    Pharmaceutical research and development (R&D) competition in the 1980s and 1990s was characterised by rising R&D expenditures, favourable returns to innovators and the introduction of many new classes of drugs with high social benefits. However, in the past 3 years, the number of new drug...

  • Drug patents: the high price of watchdog litigation. Collier, Roger // CMAJ: Canadian Medical Association Journal;6/11/2013, Vol. 185 Issue 9, pE387 

    In this article, the author discusses the growing issue of drug patents citing reference to battle between brandname drug companies and generic drug companies. According to Jim Keon, president at the Canadian Generic Pharmaceutical Association, generic drug companies act as a mediator on patents...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics